Arts & Architecture

A framework for priority setting

Description
A framework for priority setting
Published
of 7
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Related Documents
Share
Transcript
   Trends in NHS expenditure Editor —  The otherwise informative series of articles on NHS funding from the King’sFund Policy Institute were flawed in several ways. 1-4  They considered only current expenditure in England,they did not discussthe relation between declining capitalexpenditure and the private finance initia-tive, and they did not comment on theincreased transactional and capital charging costs that have followed the NHS reforms.Most importantly, none of the articlesdiscussed the implications of the govern-ment’s present plans to squeeze publicexpenditure, including NHS spending, untilthe end of the century.Bipartisan political support resulted inNHS current and capital spending in theUnited Kingdom rising by 74% (average5.1% per year) in real terms during the 14years from 1965-6 to 1979-80; the Labour party was in power for 10 of these years.Expenditure rose by 65% (average 5.0% per year) in real terms during the 13 years from1979-80 to 1992-3, when the Conservativeparty was in office. 5  After generous increases in NHSexpenditure associated with the pumppriming of the NHS reforms between1990-1 and 1991-2 and 1991-2 and 1992-3,annual increases in current and capitalspending in real terms have fallen (fig 1). The chancellor’s plans for NHS expenditureto 1999-2000 envisage a further fall inspending in real terms to zero between 1999and 2000. This unprecedented decline inthe planned rate of increase of NHS andpublic expenditure below the anticipatedexpansion of gross domestic product is sup-ported by the Labour opposition andreflects the increase in public debt under thecurrent administration, the convergence cri-teria for possible entry to Europeanmonetary union,and the desire of both par-ties to avoid suggesting to the electorate that tax rises may be in prospect. Since NHSinflation is historically higher than generalinflation, in real terms NHS spending willfall unless the Treasury’s spending limits arerelaxed. To extrapolate trend from a dataset end-ing in 1994 and to assume that NHS spend-ing will continue to increase as in the past (1970-94) seem optimistic in the light of thepresent stance of the government andopposition on public expenditure. 2 Current evidence of underfunding in the face of ris-ing demand supports a more pessimisticconclusion about the future of publiclyfunded health care in the United Kingdomunless taxation is increased. Matthew G Dunnigan  Honorary senior research  fellow in human nutrition  Royal Infirmary, Glasgow G31 2ER 1 Dixon J, Harrison A, New B. Is the NHS underfunded?  BMJ   1997;314:58-61.(4 January.)2 Harrison A, Dixon J, New B, Judge K. Can the NHS copein future?  BMJ   1997;314:139-42.(11 January.)3 Dixon J, Harris A. A little local difficulty?  BMJ   1997;314:216-9.(18 January.)4 Harrison A,Dixon J,New B,Judge K.Is the NHS sustain-able?  BMJ   1997;314:296-8.(25 January.)5 Economist  . Pocket Britain in figures.  London: Economist   , 1995. Poor recruitment to lung cancer trials Editor —  The Sheffield Lymphoma Group’srecent audit confirms that a “positiveattitude” enables high rates of recruitment (45%) to clinical trials. 1 It was frustrating tohavenofurtherinformationaboutthe7%of eligible patients who were considered for, but not entered on, studies. Why are one inseven patients not entered if less than 1%refuse, and did this ratio come closer to onein four in 1992 if,as is apparent,recruitment fell at a faster rate than referral during thelast four years of the audit? This is a potentially significant selection bias if these were not randomised controlled trials. As part of the London Lung Cancer Group, we recently audited our recruitment to trials of the commonest cancer, lung cancer. Two trials illustrate two important points.Inthepastsixmonthswehaveenteredonlyonepatient,outof23referralswithsmallcell lung cancer, to a randomised controlledtrial examining the timing of chemoradio-therapy in limited disease because of extremely stringent entry criteria. Answering precise questions reliably can be slow andlaborious,and collaboration is essential.Patients with non-small cell lung cancer areencouragedtoparticipateinthebiglung trial,examining the role of chemotherapy at every stage of the disease; patients arerandomised between palliative chemo-therapy and best supportive care or adju- vant chemotherapy and no treatment after surgery or radiotherapy. This is a perfect example of one of Hancock   et al  ’s simpleand clinically relevant studies with less strict entry criteria. In the Royal Hospitals Trust,from November 1995 to January 1997, 207patients with non-small cell lung cancer  were assessed: 99 patients were potentiallyeligible for the big lung trial, but only 21patients were recruited (21%).Many patients with advanced disease felt that something,such as chemotherapy, must be better thannothing, while many who had undergonesurgery, which they are encouraged to believe is curative,were reluctant to undergofurther treatment.Despite the meta-analysis, 2 there remainstrongly held preconceptions about the role  Advice to authors  We receive more letters than we can publish:we can currently accept only about one third.We  prefer short letters that relate to articles  published within the past four weeks.We also publish some “out of the blue”letters,which usually relate to matters of public policy.When deciding which letters to publish we  favour srcinality,assertions supported by data or by citation,and a clear prose style.Letters should have fewer than 400 words (please give a word count) and no more than five references (including one to the BMJ article to which theyrelate);references should be in the Vancouver style.We welcome pictures. Letters should be typed and signed by each author,and each author  ’ s current appointment and address should be stated.We encourage you to declare any conflict of interest.Please enclose a stamped addressed envelope if you would like toknow whether your letter has been accepted or rejected.We may post some letters submitted to us on the world wide web before we decide on  publication in the paper version.We will assume that correspondents consent to this unless theyspecifically say no. Letters will be edited and may be shortened. 7 6.96.00.63.72.21.3     1 .   5    (    P    l   a   n   n   e    d    )    0 .    3    (    P    l   a   n   n   e    d    )    0    (    P    l   a   n   n   e    d    ) 6543210     A   n   n   u   a    l   r    i   s   e    i   n    N    H    S   e   x   p   e   n    d    i   t   u   r   e    i   n   r   e   a    l   t   e   r   m   s    (    %    )    1   9   9   1  -   2   1   9   9   2  -   3   1   9   9   3  -  4   1   9   9  4  -   5   1   9   9   5  -   6   1   9   9   6  -   7   1   9   9   7  -   8   1   9   9   8  -   9   1   9   9   9  -   2   0   0   0 Financial year  Fig 1  Increases in current and capital NHSexpenditure in England between 1991-2 and1999-2000 (taken from  Financial Statement and Budget Report 1997-98  , published by HMSO in1996) Letters 974  BMJ  VOLUME 314 29 MARCH 1997  of chemotherapy in treating lung cancer  which challenge the therapeutic equipoisethat is necessary for randomised controlledtrials. It remains the case that to do what is best for an individual patient requiresfinding out what is best for that group of patients. By explaining this clearly topatients, we may marry autonomy withheteronomy. Richard T Penson  Senior registrar  Robin M Rudd  Consultant physician  Department of Medical Oncology,St Bartholomew’s Hospital, London EC1A 7BE 1 Hancock BW, Aitken M, Radstone C, Vaughan HudsonG. Why don’t cancer patients get entered into clinicaltrials? Experience of the Sheffield Lymphoma Group’scollaboration in British National Lymphoma Investiga-tion studies.  BMJ   1997;314:36-7.(4 January.)2 Non-small Cell Lung Cancer Collaborative Group.Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from52 randomised clinical trials.  BMJ   1995;311:899-909. Fatal methadone overdose Editor —  We had grandiose plans for our study of methadone related deaths 1 — until we realised that the local drug rehabilitationcommunity was more interested in bidding for a forthcoming contract to provide a methadone maintenance programme toManchester Health Authority. Our most informative contact refused to be acknowl-edged in print for fear of dismissal for revealing “commercially sensitive” infor-mation about the nature of certain bids. For these reasons, we limited ourselves to study-ing coroners’ records. We freely admit that this approach has drawbacks: for example,coroner’s records depend on appropriatereferral of cases,and they are limited to sub- jects who died within the boundaries of individual jurisdictions rather than thoseresident there at the time of death. We know that there are major difficultiesin interpreting methadone concentrationsafter death, 2 and the identification of fatalmethadone overdose requires much morethan matching a postmortem blood concen-tration with a predetermined criterion: it takes into account other findings made onnaked-eye, histological, and toxicologicalexamination,as well as considering anything known about the clinical circumstances. Weexplained this to members of Drugs North West, so we were surprised to read an accu-sation by John Merrill and colleagues that  we have exaggerated our statistics on deathscausedbymethadone 3 andamazedthattheyignore our observation that many of our subjects were killed by diverted methadone;in these subjects the concentrations appro-priate for habitual users may be invalid. If Merrill and colleagues think the pathologi-cal diagnoses are wrong, what do they think is going on? Does Manchester really have anepidemic of some mysterious disease that kills young people, leaving no visible trace,affecting only those who have recently takenmethadone? In any case, with few excep-tions,methadone concentrations in our sub- jects were much higher than those discussedin Merrill and colleagues’ letter: subjectsinvestigated by the toxicological service at Manchester Royal Infirmary showed meanconcentrations of 1057   g/1 in users of diverted methadone and 2730   g/1 inhabitual users. Incidentally, Merrill andcolleagues have overlooked a conflict of interest,which is that part of their client baseis resident within the jurisdiction of the Cityof Manchester coroner. We agree that effective services should be available to all who are dependent onopiates,but we do not think that the way for- ward is to stick one’s head firmly in the sand,ignoring deaths caused by diverted metha-done. It is clear that sloppy practices persist in the prescription, dispensation, and stor-age of methadone, 4 5 and these now requireurgent attention. Emyr W Benbow  Senior lecturer in pathology Ian S D Roberts  Lecturer in pathology University of Manchester, Manchester M13 9PT Alison Cairns  Registrar in pathology Bradford Royal Infirmary, Bradford BD9 6RJ 1 Cairns A, Roberts ISD, Benbow EW. Characteristics of fatal methadone overdose in Manchester, 1985-94.  BMJ  1996;313:264-5.(3 August.)2 Benbow EW, Roberts ISD, Cairns A. Fatal methadoneoverdose.  BMJ   1996;313;1479.(7 December.)3 Merrill J,Garvey T,Rosson C.Methadone treatment.  BMJ  1996;313;1481.(7 December.)4 Strang J, Sheridan J, Barber N. Prescribing injectable andoral methadone to opiate addicts: results from the 1995national postal survey of community pharmacies inEngland and Wales.  BMJ   1996;313:270-2.(3 August.)5 Calman L, Finch E, Powis B, Strang J. Methadonetreatment.  BMJ   1996;313;1481.(7 December.) GP cooperatives Can improve lives of doctors and care of patients Editor — Iwasstimulated,irritated,andnota little upset by the personal view “There’snothing I can do, I’m only a doctor” —  but Idid not find the article informative. 1 I am a general practitioner in Swansea  who worked hard to set up a local coopera-tive which covers about 70 000 patients, sothe anonymous article may well have beenaimed at me. I am also an enthusiastic advo-cate of emergency prehospital coronarycare and have gathered information about my own patients which shows that the timefromonsetofchestpaintoadministrationof thrombolysis is over an hour in Swansea,under the best circumstances. The argument that a general practi-tioner working out of hours is right todelay sending a patient to hospital until heor she has been to hold the hand of thepatient is absurd. If I get a call that suggestsa myocardial infarction and the ambulancecan get there before me, I rein in my enthu-siasm and do the pragmatic thing. If I canspeed things up, or the diagnosis only becomes apparent on face to face consulta-tion,then I have a definite role. To do more than this I need anelectrocardiograph, a fax machine, a defib-rillator, a fridge to store the thrombolyticdrugs, someone trained in intubation, thefull gamut of drugs to manage a cardiacarrest, and an ambulance dedicated to thepurpose. I also need to be able to focus onthis kind of case. With less than these facili-ties, I am a bumbling harmful amateurishfool, harmful to my patients and to theimage of general practitioners. The cooperative of which I am a director is too small to purchase these facilities andhas not enough members to develop a rota of the minority who have an enthusiasm for this type of work. It may not always be this way as our numbers are steadily growing.At least at present we can prioritise our work properly, we are all less tired and over- worked,and we have a clear view of our limi-tations.  Jim York  Director,Greater Swansea GP Cooperative  Brynhfryd Surgery, Brynhfryd, Swansea SA5 9DZ 1 There’s nothing I can do, I’m only a doctor.  BMJ   1997;314:759-60.(8 March.) Doctors must listen to criticism Editor — Cooperatives are clearly thriving and seem to have a bright future because of their popularity with doctors (whose per-sonal, family, and social lives are lessdisrupted) and with the government, which will, as the anonymous personal viewcorrectly states, 1 ultimately pay less as out of hours work becomes a non-core service.Cooperatives must take note of bravecomment and criticism such as that fromthis anonymous contributor. It is definitelynot good enough for the duty doctor in thecooperative to say, “There is nothing I cando; send for the ambulance.” Let the patient have a paramedic and a doctor;if this meansmore doctors from the cooperative on a shift then so be it.We have to be very carefulnot to throw out the baby of adequate care with the bathwater of tiredness and over- work. Theauthor is right insayingthat generalpractitioners are in danger of damaging thecase with the review body. It may seem that  we have backed off from the care of our patients for around half of each 24 hours;that we, as individual practitioners or partnerships, are ceasing to be available toour patients for half of their lives. To balance these remarks I should addthat I recently joined the local cooperativeand in my opinion the service provides verysound care. I have enjoyed the contact withcolleagues and the pooling of ideas andresources which have come with thecooperative, helping to overcome profes-sional isolation. We must, however, listen tocriticism and not be carried along on the bandwagon of unquestioning zeal.  John Rawlinson  General practitioner  Kimbolton, Huntingdon PE18 0JF 1 There’s nothing I can do, I’m only a doctor.  BMJ   1997;314:759-60.(8 March.) Unity of approach to out of hours care isneeded Editor —  The anonymous personal view“There’s nothing I can do,I’m only a doctor”is an example of divide and rule. 1  Anysystem for out of hours care needs to be Letters 975 BMJ  VOLUME 314 29 MARCH 1997  adequately resourced in money and staff.Most doctors, myself included, feel that thetraditional “own practice”cover has too higha cost (in many different ways) for thedoctors involved. If I worked in a coopera-tive I would feel threatened by this article. It encourages a battle between doctors when we really need to be putting our case for adequate resources to our political masters.I am 37 years old and have worked as a principalona1in3rotaformostofthepast 10 years in a rural general practice with a 400 square mile area. I hate night visits for the disturbance of sleep and the impairment of the next day’s performance. I dislike most  visits because they are such an inefficient useof my time. I feel guilty about this but havecome to the belief that all these “negativeattitudes” are in fact well within the boundsof normality. Within our practice area it is not uncommon to take 35 minutes to reach a patient even if the doctor is able to set out immediately. Any patient having a myocar-dial infarction would be distressed whileawaiting the ambulance. Doctors cannot take responsibility for all distress. I accept that the writer has chosen the one conditionin which an urgent medical visit is still themanagement of choice.The development of cooperatives, however, is largely due to risein demand for conditions for which urgent medical visits are not required. Attitudes similar to that of the writer of the personal view are preventing me fromeven discussing out of hours issues with col-leagues in neighbouring rural practices.Theout of hours commitment may lead me toleave general practice much earlier than I would have otherwise. Please let us uniteabout out of hours care, not pull each other to pieces. Nick Lattey  General practitioner  Ewyas Harold Surgery, Herefordshire HR2 0EU 1 There’s nothing I can do, I’m only a doctor.  BMJ   1997;314:759-60.(8 March.) Don’t serve rural patients well Editor —  The fashion for the development of cooperatives as a solution to out of hourscare in general practice is not universally welcomed by the profession. The anony-mous author of the personal viewadequately illustrates that what may be pro- videdisaservicethatfallsshortofdelivering the best possible care to patients in allcircumstances. This is more likely in areas remote fromambulance stations; in these areas patients view the local general practice as anemergency service.It is therefore imperativethat high quality, quickly accessible, andproperly equipped and trained generalpractitioners are available in these areas toprovide first line care. A real concern must  be that with the development of coopera-tives in rural areas that such a response will be available from neither the ambulanceservice nor general practice if a cooperativeisthemeansofprovidingoutofhourscover. Although cooperatives may adequatelyserve the needs of urban populations for  which an ambulance service is quickly avail-able, they may not serve the needs of ruralpatients at all well. D A G C Robertson  General practitioner   The Surgery, New Pitsligo, Fraserburgh AB43 4NE 1 There’s nothing I can do, I’m only a doctor.  BMJ   1997;314:759-60.(8 March.) Offer a vehicle for change Editor —  The sour and anonymous author of the personal view on general practitioner cooperatives uses anecdotal unattributal evi-dence to denigrate an entire system. 1 Firstly,he needs to question his paramedic ambu-lance response time as it falls well short of an acceptable standard. Secondly, he shouldsuggest that his local cooperative review itsmanagement protocol for patients withchest pain, and perhaps he should contrib-ute to the exercise.General practitioner cooperatives are inmany cases in their infancy.They are also not a panacea for the ills that currently beset gen-eral practice in the United Kingdom. Theyare,however,anexcitingdevelopmentinpro- viding care to patients. They bring together large numbers of working general practition-ers, who then have a forum to discuss anddebate issues such as how quality is definedand measured. They are not small unrepre-sentative cliques, nor are they purely aca-demic bodies. They are a true mixture of  working doctors who care about their patients and also feel that they havesomething to contribute to the process of change in primary care.Doctors who work in our area are better equipped than ever before. They have hadthe opportunity for advanced resuscitationtraining provided by the cooperative (which we have also offered to our non-member colleagues). There is a driver trained in first aid at the doctor’s side. Voice recording of every call, and highly skilled telephonists working to triage protocols arranged withour ambulance trust,mean that our “pain toneedle time” is as good as any, and better than most, for giving streptokinase inmyocardial infarction. Our local cottagehospital has a resident doctor for the first time in 50 years; as a result, triage and man-agement times in accident and emergencyare excellent. Our patients speak well of theservice we provide. In six months of opera-tion we have had no formal complaints.Our profession has to live in a changing  world and must adapt to increasing publicdemand on our services. We must changethe career structure in general practice andaddress the issues of recruitment and remu-neration. At the same time as doing all of this we must always seek to improve thequality of care that we provide for our patients. Good patient care, good training and working conditions for staff, as well asgood remuneration, are all laudable goals. The cooperatives offer one vehicle to helptackle these issues out of hours. Kevin McKenna  Medical director  Northern Doctors Urgent Care, PO Box 2, Ashington, Northumberland NE63 0YY 1 There’s nothing I can do, I’m only a doctor.  BMJ   1997;314:759-60.(8 March.) More points must be addressed Editor — In response to the anonymous per-sonalview 1 onthefailureofthelocalgeneralpractitioner cooperative to visit a patient  with chest pain, I would like to make threepoints.Firstly, while many general practitioners will sympathise with the writer’s regret at thechange in the personal relationship betweendoctors and patients over the past 20 years,most will recognise that cooperatives are a consequence of this change rather than a cause.Secondly, in attacking cooperatives onthe issue of failing to visit a patient withchest pain, the writer is confusing thegeneral argument about cooperatives withthe separate specific argument about visiting patients with chest pain. In each individualsituation, whether it is in the patient’s best interests for the doctor to visit,call an ambu-lance,or do both is a dilemma for all generalpractitioners. Some cooperatives argue that a fresh doctor working a short shift out onthe road in a car fully equipped withdefibrillator, oxygen, etc, is in a better position to respond to a patient with chest pain at 4 00 am than the doctor hauled from bed exhausted at the end of another  weekend on call. Thirdly, I accept that change polarisesopinion and can lead to the taking up of extreme positions —  but to write anony-mously to the BMJ comparing your col-leagues in the local cooperative to Nazis isperhaps going too far. Patrick Holmes  General practitioner  Stroud Health Centre, Stroud, GloucestershireGL5 4BH 1 There’s nothing I can do, I’m only a doctor.  BMJ   1997;314:759-60.(8 March.) Catching glaucoma Editor — It was unfortunate that the sum-mary in Minerva  1 of a recent study of mis-diagnosis of patients presenting withglaucoma  2 failed to specify that the type of glaucoma to which it referred was acuteangle closure only.Reduction in vision and a redeyewereconsistentsignsinthisgroupof patients with acute angle closure glaucoma,and we agree that patients with these signsshouldbereferredpromptlyforophthalmo-logical assessment. The prevalence of primary angle closureglaucoma in the general population agedover 40 years is only 1 in 1000,however,andprimary open angle glaucoma occurs in 1 in200 of the general population aged over 40. 3  These patients typically do not have a redeye, and reduction in vision occurs only inadvanced disease. This condition may bedetected by screening of intraocular pres-sure, optic disc cupping, and visual fielddefects, and ideally should be referred for ophthalmological management before vision deteriorates. It is important to screen Letters 976  BMJ  VOLUME 314 29 MARCH 1997  for primary open angle glaucoma and torefer patients early even though they haveno symptoms since this disease accounts for an eighth of blind registrations in Britain. 4 Fiona M Chapman  Senior registrar in ophthalmology Peter S Phelan  Consultant ophthalmologist  Sunderland Eye Infirmary, Sunderland SR2 9HP 1 Minerva.  BMJ   1997;314:156.(11 January.)2 Siriwardena D, Arora AK, Fraser SG, McClelland HK,Claoue C. Misdiagnosis of acute angle closure glaucoma.  Age Ageing   1996,25:421-3.3 Kanski JJ.  Clinical ophthalmology.  London: ButterworthHeinemann,1994.4 Thompson JR, Du L, Rosenthal AR. Recent trends in theregistration of blindness and partial sight in Leicester-shire.  Br J Ophthalmol   1989;73:95-9. Cyclists should wear helmets Editor —  We are not surprised that our letter on cycle helmets 1 evoked such a strong response. 2  We chose to ignore accidentsinvolving cars because most cyclists’ headinjuries are not caused in this way.The mainpurpose of helmets is to protect the head insituations other than car accidents. We too hope for a more fair environ-ment with fewer cars, all being driven slowlyand carefully. That there may be an element of victim blaming in helmet laws when aninjury does involve a car is not sufficient rea-son for cyclists to serve as martyrs in thisdispute. Even those opposed to helmet lawsmust concede that others are also blameworthy — for example,those who fail tomaintain roads in a safe condition. So long as cyclists remain victims of road transport policies that favour cars it is irresponsiblenot to press for a helmet law.Richard Keatinge believes that cyclists who wear helmets are more careful, thusexplaining why studies show helmets to beprotective. 2  This belief is unsupported andignores the fact that the best studies usecyclists with other injuries as controls. 3 4 Moreover, others postulate the opposite,equally unproved,notion that helmets give a false sense of security, thus prompting care-lessness. In addition, data from Australia show a reduction in both cycling andinjuries after the introduction of a helmet law. Precisely how such a law works matterslittle if the public health issue is to reducehead injuries.Some critics believe that the health ben-efits of cycling outweigh the dangers posedto cyclists. 2  This is not established by thesources cited, and those who abandoncycling may substitute better modes of aero- bic activity. No one knows how long thepique of cyclists will last; it seems unlikelythat many would choose to abandon thisactivity forever rather than wear a helmet or to sustain a blow to the head without a helmet.So for many the issue comes down tofreedom of choice and arguments against a nanny state. Interestingly, such concerns areno longer heard about compulsory seatbelt requirements and similar public healthmeasures in which a small price must bepaid for the greater good. After all, most readers live in societies where the costs of caring for the tragic sequelae of some headinjuries are born by families and communi-tiesandnotbythepersonwhohasexercisedthis precious freedom. In this context weconfess to being, as our pipe-smoking andhelmetless cyclist critic G H Hall suggests,risk averse do-gooders. 2 Barry Pless  Editor,“Injury Prevention”  Montreal Children’s Hospital, Montreal, QuebecH3H 1P3, Canada  Ron Davis  Editor,“Tobacco Control”  Center for Health Promotion and DiseasePrevention, Henry Ford Health System, Detroit,MI 48202-3450, USA 1 Davis RM, Pless B. Evidence shows that cyclists should wear helmets.  BMJ   1996;313;629.(7 September.)2 Correspondence. Cyclists should wear helmets.  BMJ  1997;314;69-70.(4 January.)3 Thompson DC, Rivara FP, Thompson RS. Effectivenessof bicycle safety helmets in preventing head injuries: Acase-control study.  JAMA  1996;276:1968-73.4 Thompson DC, Nunn ME, Thompson RS, Rivara FP.Effectiveness of bicycle safety helmets in preventing seri-ous facial injury.  JAMA  1996;276:1974-5.  Depression and the menopause Oestrogens improve symptoms in somemiddle aged women Editor — In her editorial Myra S Hunter repeatedly makes the point that depressionshould not automatically be blamed on themenopause. 1 Nobody would disagree withthat, but we need to know whether depression is more common in women inthe years running up to the menopause, whether it is related to hormonal changes,and whether it can be effectively treated byhormone replacement.Hunter’s monocular vision on thesubject and her eccentric choice of refer-ences do not allow us to answer any of thesequestions.The menopause is the time of thelast menstrual period and therefore state-ments such as “a longer menopause (at least 27 months) was associated with an increased but transitory risk of depression” are not easy to interpret. 1 She is probably correct inthat it is difficult to associate either the causeor the treatment of postmenopausal depres-sion with oestrogens, and our studies haveshown considerable improvement only inpremenopausal women. 2 3 Indeed, many women feel well for the first time in manyyears when the menopause removes their premenstrual syndrome, heavy painful peri-ods, menstrual migraine, and chronic cycli-cal depression.This improvement of depres-sion has not been detected in prospectivepsychological studies,so it is no wonder that the same studies, with their imperfect methodology, have failed to find an increasein depression within this heterogeneousgroup of women. The excess of depression in womencompared with men occurs at times of great hormonal fluctuations — at the time of puberty, in the postnatal period, andpremenstrually — and it is worst in the fewyears before menstrual cycles end. At thistime the worsening symptoms of premen-strual tension with age blend with the worst years of the climacteric. These wretchedlydepressed women in their 40s usuallyrespond well to oestrogen treatment rather than to the psychoactive drugs that remainthe first line treatment of psychiatrists. There are now many randomised trialsof oestrogen treatment summarised else- where but ignored in the editorial whichshould encourage the use of oestrogens,not of course automatically but in perimeno-pausal women who have markers in their history indicating that the depression may be responsive to hormones. 4  These are a history of having a good affect during preg-nancy,a history of postnatal depression,anda history of premenstrual depression, withthe current depression being or having beencyclical — that is, ovarian. Menstrual migrainecompletes this quartet of clinical markers.Depressed women are suffering as muchfrom the conflict between psychiatrists,psychologists, and doctors who prescribeoestrogens as from their disease. Thisprofessional conflict is in part territorial andin part due to ignorance,which is supported by this biased editorial from a clinicalpsychologist who knows all of the opposing  views but seems to ignore them. Perhapsdepression is thought to be too complex a condition to be treated by something as sim-ple as oestrogens or by people as simple asgynaecologists.Indeed, the treatment of manydepressed middle aged women may bemore simple and more successful than thecurrent choices used by psychiatrists.  John Studd  Consultant gynaecologist  Chelsea and Westminster Hospital, LondonSW10 9NH 1 Hunter MS. Depression in the menopause.  BMJ   1996;313:1217-8.(16 November.)2 Montgomery JC,Brincat M,Tapp A,Fenwick PBC,Studd JWW. Effect of oestrogen and testosterone implants onpsychological disorders in the climacteric.  Lancet  1987;i:297-9.3 Watson NE, Studd JWW, Savvas M, Gamett T, Baber RJ. Treatment of severe premenstrual syndrome with oestra-diol patches and cyclical oral norethisterone.  Lancet  1989;i:730-4.4 Studd JWW, Smith RNJ. Oestrogens and depression.  Menopause   1994;1:18-23. Author’s reply Editor — In my editorial I put forward a  biopsychosocial model and reviewed thefindings from major prospective epidemio-logical studies. To be accused of bias andmonocular vision by John Studd is ironic:heproposes an entirely biological explanationand treatment for depression in middleaged women, ignoring the results from sub-stantial bodies of crosscultural, sociological,and psychological research and failing tomention the review article by LouiseNicol-Smith that my editorial introduced. 1 She concluded that there was no evidence at present to maintain that menopause causesdepression, and her detailed analysis failedto show a relation between depression andthe perimenopause or between depressionand age (40 to 60 years).Studd then shifts the argument awayfrom the menopause to hormonal fluctua-tions as a major cause of the sex differencein depression between women and men.Hisquartet of clinical markers is presumably Letters 977 BMJ  VOLUME 314 29 MARCH 1997   based on his experience of a subsample of a clinic population, which he describes as“wretchedly depressed women in their 40s.”It is important not to generalise from women attending menopause clinics tomost middle aged women 2 ; this kind of gen-eralisation perpetuates negative images of middle aged women. Developmental andpsychosocial factors are major causes of depression in women who are depressedduring the reproductive cycle. 3 Iagreethatfurtherresearchisneededtoinvestigate the relation between changing concentrations of hormones and mood, but as yet no hormonal substrate has beenfound for premenstrual syndrome or for depression during the climacteric.Studd references two randomised con-trolled trials carried out by his researchteam. One shows that oestradiol patchesreduce reports of premenstrual symptoms. 4  The other compared the effects of oestrogenimplants (50 mg) with oestrogen andtestosterone and a placebo. 5 Despite aninitial difference between oestrogen andplacebo two months after implantation inthe perimenopausal women in the study,there were no overall significant differences between the perimenopausal or postmeno-pausal group and the placebo group between two and four months after implan-tation or for the postmenopausal groupafter two months. Thus the initial positiveeffect for the perimenopausal women seemsto have been transitory. Moreover, theresults of treatment studies do not necessar-ily provide evidence about the cause of a clinical problem. Myra Hunter  Clinical psychologist  Subdepartment of Clinical Psychology,University College London, London WC1E 6BT 1 Nicol-Smith L. Causality, menopause and depression: a critical review of the literature.  BMJ   1996;313:1129-32.(16 November.)2 Morse CA, Smith A, Dennerstein L, Green A, Hopper J,Berger H. The treatment seeking woman at menopause.  Maturitas   1994;18:161-73.3 Brown GW, Harris T.  Social srcins of depression  . London: Tavistock Publications,1978.4 Watson NE, Studd JWW, Savvas M, Gamett T, Baber RJ. Treatment of severe premenstrual syndrome with oestra-diol patches and cyclical oral norethisterone.  Lancet  1989;i:730-4.5 Montgomery JC, Appelby L, Brincat M, Versi E, Tapp A,Fenwick PBC,  et al  . Effect of oestrogen and testosteroneimplants on psychological disorders in the climacteric.  Lancet   1987;i:297-9. Circaseptennial rhythm is anartefact  Editor —  The strange result on circasepten-nial rhythm in ear growth 1 is probably dueto the way the data were processed rather than any properties of the human body.Given ear size at age t as x t  , the authors cal-culated y t  =(x t  +  x t-1 +  x t-2 -x t-3 -x t-4 -x t-5 )/9 as a smoothed measure of ear growth. This is a moving average, and it is a well known phe-nomenon (the Slutsky effect), that moving averages of random data seem to havecyclical properties. 2 For example, I applied the abovemoving average to some random data withthe same length as the data used by Verhulst and Onghena and obtained the periodo-gram in figure 1.This has a peak at six years,and the peak is significant (P=0.066) onFisher’s test.This period is close to the sevenyears found for ear growth but is entirelyspurious. Non-linear trends in the real data could have smeared the peak they foundover several frequencies and produced a seven year apparent cycle. M J Campbell  Reader in medical statistics  Medical Statistics and Computing, SouthamptonGeneral Hospital, Southampton SO16 6YD 1 Verhulst J, Onghena P. Circaseptennial rhythm in ear growth.  BMJ   1996;313:1597-8.(21-28 December.)2 Slutsky E. The summation of random causes as thesource of cyclic processes.  Econometrica   1937;5:105-46. Comorbidity increases benefit of anticoagulation in patients with atrial fibrillation Editor —  The recent paper from M Langen- berg and colleagues confirms the highprevalence of atrial fibrillation in a northernEuropean population aged 60 years andover. 1 In conjunction with the cohort studydata this further establishes atrial fibrillationas a major contributor to the total burden of stroke in the population. 2 If these figures aretransferable to the United Kingdom, about 630 000 patients have atrial fibrillation inthis age group,of whom 30 000 have strokeseach year. The authors comment that the highlevel of comorbidity found in their studymight complicate the decision to giveanticoagulation treatment, and further stud-ies are required to clarify this. However, theprevalence of the comorbid conditionsreported in this paper is practically identicalto that described in the meta-analysis of treatment trials to which the authors refer. 3  The interpretation of this similarity is that clinicians deciding how to manage a patient in atrial fibrillation in primary care can nowhave even greater confidence that the 68%relative risk reduction observed in the trialsof anticoagulation can reasonably beexpected to be obtained in the wider popu-lation of patients with atrial fibrillation.Hypertension, diabetes, and a history of transient ischaemic attacks, stroke, or myo-cardial infarction were found in the meta-analysis to increase the absolute benefit from anticoagulation.Thus 14 patients agedover 75 with one or more of thesecomorbidities need to be treated for oneyear to prevent an event.For similar patients without any of these conditions the number needed to be treated is 56. 4 It is important that one lesson learnt from the treatment of hypertension — that those who benefit most from treatment arethose who are most at risk to begin with — isnow applied to the management of atrialfibrillation.Thus the older patient with atrialfibrillation and another condition associated with cerebrovascular disease should not beoverlooked just because the treatment seems to be more complex. Stephen Morgan  Wellcome Trust research fellow  University of Southampton, School of Medicine,Primary Medical Care, Aldermoor Health Centre,Southampton SO16 5ST 1 Langenberg M, Hellemons BSP, van Ree JW, Vermeer F,Lodder J,Schouten HJA,  et al  .Atrial fibrillation in elderlypatients: prevalence and comorbidity in general practice.  BMJ   1996;313:1534.(14 December.)2 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly.  Arch Intern Med  1987;147:1561-4.3 Atrial Fibrillation Investigators. Risk factors for strokeand efficacy of antithrombotic therapy in atrial fibrilla-tion.  Arch Intern Med   1994;154:1449-57.4 Morgan S, Mant D. Warfarin in stroke prevention.  Br J Gen Pract   1995;45:503. Psychological rehabilitationafter myocardial infarction Training of therapists may haveinfluenced usefulness of programme Editor — It seems ironic that the issue of 14Decembercontainedbothaneditorialonthe effectiveness of cognitive behaviouraltreatment  1 and a study of rehabilitation after myocardial infarction with negative results. 2  Although two possible explanations aredealt with in Richard Mayou’s editorial (that many of the control group had goodoutcomes anyway and that the treatment arm offered a uniform treatment for a heterogeneous range of complaints), 3 thereare other important issues that merit discussion.DA Jones and RR West set out a number of goals (provide information, increaseawareness of stress, teach relaxation,improve stress management, promote posi-tive adjustment to illness, and increaseconfidence) with the presumed hypothesisthat attainment of these aims would reducemorbidity and mortality. Was the lack of effect due to failure to teach a programmethat could be utilised by the treated patients,or are psychological techniques ineffectivein reducing mortality? The lack of anychange in anxiety (albeit measured by anodd choice of instrument) would suggest theformer.Psychological therapies are very differ-ent from, say, giving a drug because theexact components and quality are not speci- 1.00.80.60.40.20     P   e   r    i   o    d   o   g   r   a   m 2 4 6 8 10 20 40 Years  Fig 1  Periodogram of random data Letters 978  BMJ  VOLUME 314 29 MARCH 1997
Search
Related Search
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks